Narrow search
Showing 1 - 10 of 10,474
Cover Image
Does health technology assessment compromise access to pharmaceuticals?
Büssgen, Melanie; Stargardt, Tom - In: The European journal of health economics 24 (2023) 3, pp. 437-451
Persistent link: https://www.econbiz.de/10014328020
Cover Image
From scientific research to healthcare markets : empirical essays on the economics of pharmaceutical innovation
Byrski, Dennis - 2021
Persistent link: https://www.econbiz.de/10012816525
Cover Image
Impact of price control on pharmaceutical sector with reference to India
Kolte, Ashutosh; Mal, Hoshiar; Fulambrikar, Mugdha; … - In: International journal of intelligent enterprise 8 (2021) 1, pp. 90-104
Persistent link: https://www.econbiz.de/10012512495
Cover Image
Pharmaceutical regulation and health policy objectives
Birg, Laura - 2013
public expenditure, limiting financial exposure of patients, improving access to pharmaceuticals, and stimulating competition …
Persistent link: https://www.econbiz.de/10010224844
Cover Image
Fair prices for medicines? : exploring competent authorities’ and public payers’ preferences on pharmaceutical policies
Vogler, Sabine - In: Empirica : journal of european economics 46 (2019) 3, pp. 443-469
Persistent link: https://www.econbiz.de/10012242289
Cover Image
Pharmaceuticals industry and regulation in India : a note
Motkuri, Venkatanarayana; Mishra, Rudra N. - 2018
Persistent link: https://www.econbiz.de/10012506948
Cover Image
Pharmaceutical governance
Biehl, João - In: Global pharmaceuticals : ethics, markets, practices, (pp. 206-239). 2006
Persistent link: https://www.econbiz.de/10003415524
Cover Image
The new political economy of pharmaceuticals : production, innnovation and TRIPS in the global south
Löfgren, Hans (contributor) - 2013
"Some two decades will shortly have passed since the WTO's Trade Related Aspects of Intellectual Property Rights agreement came into force in 1995. TRIPS is widely considered to have had a negative impact on access to medicines through its rules on pharmaceutical patents. This volume is the...
Persistent link: https://www.econbiz.de/10009793209
Cover Image
R&D and market size : who benefits from orphan drug legislation?
Gamba, Simona; Magazzini, Laura; Pertile, Paolo - In: Journal of health economics 80 (2021), pp. 1-22
Persistent link: https://www.econbiz.de/10013179155
Cover Image
Special FDA designations for drug development : orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Michaeli, Daniel; Michaeli, Christoph T.; Albers, Sebastian - In: The European journal of health economics 25 (2024) 6, pp. 979-997
Persistent link: https://www.econbiz.de/10014633366